SNORD110: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD110

NCBI ID: G692213

SNORD110

Other Name(s): small nucleolar RNA, C/D box 110 | HBII-55 | Small nucleolar RNA, C/D box 110

SNORD110: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD110, which is located within the C/D box 110 of the 28S rRNA molecule. The functions of SNORD110 have been extensively studied, and its potential as a drug target or biomarker continue to attract researchers' interest.

SNORD110 is a 28S rRNA molecule that contains a unique fMet-endonuclease-like activity (FEnL-like) at its C-terminus. FEnL-like activity is a hallmark of the Enrichment for Nucleotide-binding Enzymes (ENE) domain, which is a conserved family of RNA-binding proteins that play a crucial role in various cellular processes, including gene regulation, DNA replication, and repair, among others. The NED-like activity of SNORD110 was first identified and characterized by researchers using a variety of bioinformatics tools , such as RNA-Folding Predictor (RFP), RNA-Seq, and interaction assays.

SNORD110 functions as a negative regulator of gene expression by binding to specific target mRNAs and preventing their translation into proteins. Studies have shown that SNORD110 can interact with a wide range of snRNAs, including those involved in cell growth, cell cycle progression, DNA replication, and repair. Additionally, SNORD110 has been shown to play a role in regulating gene expression in various organisms, including humans. For example, studies have shown that SNORD110 is involved in the regulation of cell adhesion, stem cell maintenance, and tissue repair.

The potential drug target status of SNORD110 is supported by its expression and activity in various cell types, including cancer cells. For instance, studies have shown that SNORD110 is expressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, experiments have shown that inhibition of SNORD110 can lead to a decrease in cancer cell proliferation and a regression of cancer growth. These findings suggest that SNORD110 may be an attractive drug target for cancer treatment.

SNORD110 has also been shown to be a potential biomarker for various diseases, including cancer. For example, studies have shown that SNORD110 is overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, analyzes of gene expression data have shown that SNORD110 is involved in the regulation of important cellular processes, including cell growth, apoptosis, and inflammation. These findings suggest that SNORD110 may be a valuable biomarker for cancer diagnosis and treatment.

In conclusion, SNORD110 is a well-characterized and functionally characterized small nucleolar RNA that has the potential to be a drug target or biomarker. Its unique FEnL-like activity and its interaction with various snRNAs make it an attractive candidate for drug development. Furthermore, its expression and activity in various cell types, including cancer cells, suggest that it may be a valuable biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of SNORD110 in various cellular processes and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 110

The "SNORD110 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD110 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets